Work

Phase I Study of Bortezomib, Fludarabine, and Melphalan, with or without Total Marrow Irradiation as Conditioning for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-Risk or Relapsed/Refractory Multiple Myeloma

Year: 2023

Type: article

Study design: Clinical Trial

Source: International Journal of Radiation Oncology*Biology*Physics

DOI: 10.1016/j.ijrobp.2023.06.069

Authors: C.J. Ladbury, J.F. Sanchez, A. Chowdhury, J. Palmer, A. Liu, A. Stein, M. Htut, L. Farol, J.L. Cai, G. Somlo, M. Rosenzweig, J.Y.C. Wong, F. Sahebi

Institution: City Of Hope National Medical Center

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4387208031

FWCI:

Cites:

Cited by:

Related to: 10